Treatment with luteinizing hormone-releasing hormone antagonist SE-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice

W. Shirahige, C. B. Cook, J. Pinski, G. Halmos, R. Nair, Andrew V Schally

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist (D-Trp6]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6; D-Ala10] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp6]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp6] LH-RH were injected s.c. at doses of 100 μg/day, and RC-3095 was injected at a dose of 40 μg/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp6] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects, of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.

Original languageEnglish
Pages (from-to)1031-1035
Number of pages5
JournalInternational Journal of Oncology
Volume5
Issue number5
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Hormone Antagonists
Epidermal Growth Factor Receptor
Heterografts
Nude Mice
Gonadotropin-Releasing Hormone
Messenger RNA
Gastrin-Releasing Peptide
Bombesin
Neoplasms
Ovarian epithelial cancer
cetrorelix
Growth
Tumor Burden
Epidermal Growth Factor
Binding Sites
Membranes

Keywords

  • Epidermal growth factor receptor
  • LH-RH analogs
  • Northern blot analysis
  • Nude mice
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{8821812625ad47c29dc45e5231ff6b9f,
title = "Treatment with luteinizing hormone-releasing hormone antagonist SE-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice",
abstract = "The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist (D-Trp6]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6; D-Ala10] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp6]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp6] LH-RH were injected s.c. at doses of 100 μg/day, and RC-3095 was injected at a dose of 40 μg/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp6] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects, of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.",
keywords = "Epidermal growth factor receptor, LH-RH analogs, Northern blot analysis, Nude mice, Ovarian carcinoma",
author = "W. Shirahige and Cook, {C. B.} and J. Pinski and G. Halmos and R. Nair and Schally, {Andrew V}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "1031--1035",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Treatment with luteinizing hormone-releasing hormone antagonist SE-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice

AU - Shirahige, W.

AU - Cook, C. B.

AU - Pinski, J.

AU - Halmos, G.

AU - Nair, R.

AU - Schally, Andrew V

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist (D-Trp6]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6; D-Ala10] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp6]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp6] LH-RH were injected s.c. at doses of 100 μg/day, and RC-3095 was injected at a dose of 40 μg/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp6] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects, of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.

AB - The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist (D-Trp6]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6; D-Ala10] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp6]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp6] LH-RH were injected s.c. at doses of 100 μg/day, and RC-3095 was injected at a dose of 40 μg/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp6] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects, of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.

KW - Epidermal growth factor receptor

KW - LH-RH analogs

KW - Northern blot analysis

KW - Nude mice

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027996773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027996773&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027996773

VL - 5

SP - 1031

EP - 1035

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -